The Altair Lunar Lander will enable astronauts to learn to live and work on the moon for extended periods of time, providing the experience needed to expand human exploration farther into the solar system. My overriding recommendation: Use independent and complementary [sometimes referred to as 'orthogonal'] techniques to disambiguate confounding/interfering signals. E.g.: a mass spectrometer ['MS'], which currently serves as a Majority Constituent Analyzer ['MCA'] can be very valuable in detecting the presence of a gaseous specie, so long as it falls on a mass-to-charge ratio ['m/z'] that is not already occupied by a majority constituent of cabin air. Consider the toxic gas, CO. Both N{sub 2} and CO have parent peaks of m/z = 28, and CO{sub 2} has a fragment peak at m/z = 28 [and at 16 and 12], so the N{sub 2} and CO{sub 2} m/z=28 signals could mask low, but potentially-dangerous levels of CO. However there are numerous surface-sensitive CO detectors, as well as tunable-diode-laser-based CO sensors that could provide independent monitoring of CO. Also, by appending a gas chromatograph ['GC'] as the front-end sample processer, prior to the inlet of the MS, one can rely upon the GC to separate CO from N{sub 2} …

A letter report issued by the Government Accountability Office with an abstract that begins "Tens of thousands of women die each year from breast or cervical cancer. While screening and early detection through mammograms and Pap tests--followed by treatment--can improve survival, low-income, uninsured women are often not screened. In 1990, Congress authorized the Centers for Disease Control and Prevention (CDC) to fund screening and diagnostic services for such women, which led CDC to establish the National Breast and Cervical Cancer Early Detection Program. The Breast and Cervical Cancer Prevention and Treatment Act of 2000 was also enacted to allow states to extend Medicaid eligibility to women screened under the Early Detection Program and who need breast or cervical cancer treatment. Screened under the program is defined, at a minimum, as screening paid for with CDC funds. GAO examined the Early Detection Program's screening of eligible women, states' implementation of the Treatment Act, Medicaid enrollment and spending under the Treatment Act, and alternatives available to women ineligible for Medicaid under the Treatment Act. To do this, GAO compared CDC data on women screened by the Early Detection Program from 2002 to 2006 with federal estimates of the eligible population, surveyed program …